These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9620221)
1. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. Voelcker G; Bielicki L; Hohorst HJ J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221 [TBL] [Abstract][Full Text] [Related]
2. Metabolism and transport of oxazaphosphorines and the clinical implications. Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888 [TBL] [Abstract][Full Text] [Related]
3. Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier. Voelcker G Anticancer Drugs; 2021 Jan; 32(1):61-65. PubMed ID: 32701559 [TBL] [Abstract][Full Text] [Related]
4. The enzymatic basis of cyclophosphamide specificity. Hohorst HJ; Bielicki L; Voelcker G Adv Enzyme Regul; 1986; 25():99-122. PubMed ID: 3028054 [TBL] [Abstract][Full Text] [Related]
5. Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters. Hohorst HJ; Bielicki L; Müller K; Voelcker G J Cancer Res Clin Oncol; 1988; 114(3):309-11. PubMed ID: 3384844 [TBL] [Abstract][Full Text] [Related]
6. Causes and possibilities to circumvent cyclophosphamide toxicity. Voelcker G Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797 [TBL] [Abstract][Full Text] [Related]
7. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester. Voelcker G; Hohorst HJ J Cancer Res Clin Oncol; 1998; 124(6):297-300. PubMed ID: 9692835 [TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Friedman OM; Wodinsky I; Myles A Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209 [TBL] [Abstract][Full Text] [Related]
9. Design of new oxazaphosphorine anticancer drugs. Liang J; Huang M; Duan W; Yu XQ; Zhou S Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192 [TBL] [Abstract][Full Text] [Related]
10. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine. Voelcker G; Pfeiffer B; Schnee A; Hohorst H J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245 [TBL] [Abstract][Full Text] [Related]
11. Activity of 17 beta-hydroxy-3-aza-A-homo-4 alpha-androsten-4-one-p-N, N-bis(2-chloroethyl)aminophenoxyacetate (NSC-620480) in P388 leukemia. Activity of steroidal lactams in Ehrlich tumor. Catsoulacos P; Pairas G Methods Find Exp Clin Pharmacol; 1990 Sep; 12(7):501-5. PubMed ID: 2087151 [TBL] [Abstract][Full Text] [Related]
12. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives. Peter G; Wagner T; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218 [TBL] [Abstract][Full Text] [Related]
13. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide. Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053 [TBL] [Abstract][Full Text] [Related]
14. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. Voelcker G; Wagner T; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216 [TBL] [Abstract][Full Text] [Related]
15. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). Lelieveld P; van Putten LM Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468 [TBL] [Abstract][Full Text] [Related]